CLRB · Insider Trading
Cellectar Biosciences INC NEW
Every open-market purchase and sale reported by CLRB officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-10 | Stefan Loren | — | A | +15,000 deriv. | — |
| 2026-07-08 | Asher Chanan-Khan | Director | A | +25,000 deriv. | — |
| 2026-07-08 | Frederick W Driscoll | Director | A | +25,000 deriv. | — |
| 2026-07-08 | John Neis | Director | A | +25,000 deriv. | — |
| 2026-07-08 | James V Caruso | President & CEO | A | +250,000 deriv. | — |
| 2026-07-08 | Stefan Loren | — | A | +15,000 deriv. | — |
| 2026-07-08 | Andrew Gu | Director | A | +25,000 deriv. | — |
| 2026-07-08 | Douglas J Swirsky | Director | A | +37,500 deriv. | — |
| 2026-07-08 | Chad J Kolean | CFO | A | +92,000 deriv. | — |
| 2026-07-08 | Jarrod Longcor | Chief Operating Officer | A | +118,000 deriv. | — |
| 2026-05-11 | Jarrod Longcor | Chief Operating Officer | Buy | +8,680 | +$25.00K |
| 2026-05-11 | James V Caruso | Chief Executive Officer | Buy | +8,680 | +$25.00K |
| 2025-12-16 | John Neis | Director | Sell | −198 | −$732 |
| 2025-07-03 | Jarrod Longcor | Chief Operating Officer | Buy | +10,000 | +$49.90K |
| 2025-07-03 | James V Caruso | Chief Executive Officer | Buy | +10,000 | +$49.90K |
| 2025-07-03 | Chad J Kolean | Chief Financial Officer | Buy | +5,000 | +$24.95K |
| 2025-03-12 | Jarrod Longcor | Chief Operating Officer | Buy | +30,000 | +$8.40K |
| 2025-02-18 | Douglas J Swirsky | Director | A | +90,000 deriv. | — |
| 2025-02-18 | James V Caruso | President and CEO | A | +900,000 deriv. | — |
| 2025-02-18 | Chad J Kolean | Chief Financial Officer | A | +290,000 deriv. | — |
| 2025-02-18 | Jarrod Longcor | Chief Operating Officer | A | +500,000 deriv. | — |
| 2025-02-18 | John Neis | Director | A | +60,000 deriv. | — |
| 2025-02-18 | Frederick W Driscoll | Director | A | +60,000 deriv. | — |
| 2025-02-18 | Asher Chanan-Khan | Director | A | +60,000 deriv. | — |
| 2025-02-18 | Stefan Loren | Director | A | +60,000 deriv. | — |
| 2024-06-18 | Darrell Shane Lea | Chief Commercial Officer | A | +260,000 deriv. | — |
| 2024-06-18 | Andrei Shustov | Senior Vice President, Medical | A | +260,000 deriv. | — |
| 2024-06-18 | Frederick W Driscoll | Director | A | +60,000 deriv. | — |
| 2024-06-18 | John Neis | Director | A | +60,000 deriv. | — |
| 2024-06-18 | Asher Chanan-Khan | Director | A | +60,000 deriv. | — |
| 2024-06-18 | Stefan Loren | Director | A | +60,000 deriv. | — |
| 2024-06-18 | Douglas J Swirsky | Director | A | +90,000 deriv. | — |
| 2024-06-18 | Chad J Kolean | Chief Financial Officer | A | +290,000 deriv. | — |
| 2024-06-18 | Jarrod Longcor | Chief Operating Officer | A | +500,000 deriv. | — |
| 2024-06-18 | James V Caruso | President and CEO | A | +900,000 deriv. | — |
| 2023-12-12 | Jarrod Longcor | Chief Operating Officer | A | +42,927 | — |
| 2023-12-12 | Chad J Kolean | Chief Financial Officer | A | +42,554 | — |
| 2023-12-12 | Darrell Shane Lea | Chief Commercial Officer | A | +39,599 | — |
| 2023-12-12 | James V Caruso | President and CEO | A | +40,596 | — |
| 2023-12-12 | Andrei Shustov | Senior Vice President, Medical | A | +47,856 | — |
| 2023-06-28 | Frederick W Driscoll | Director | A | +25,000 deriv. | — |
| 2023-06-28 | Douglas J Swirsky | Director | A | +37,500 deriv. | — |
| 2023-06-28 | Asher Chanan-Khan | Director | A | +25,000 deriv. | — |
| 2023-06-28 | Stefan Loren | Director | A | +25,000 deriv. | — |
| 2023-06-28 | John Neis | Director | A | +25,000 deriv. | — |
| 2023-03-16 | Andrei Shustov | Senior Vice President, Medical | A | +100,000 deriv. | — |
| 2023-01-18 | James V Caruso | President and CEO | A | +261,000 deriv. | — |
| 2023-01-18 | Jarrod Longcor | Chief Operating Officer | A | +144,000 deriv. | — |
| 2023-01-18 | Chad J Kolean | Chief Financial Officer | A | +104,000 deriv. | — |
| 2022-12-15 | Darrell Shane Lea | Chief Commercial Officer | A | +100,000 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Jarrod Longcor | Chief Operating Officer | 20,451 | $24.75K |
| James V Caruso | President & CEO | 20,318 | $24.58K |
| Chad J Kolean | CFO | 6,418 | $7.77K |
| Douglas J Swirsky | Director | 83 | $100 |
| Frederick W Driscoll | Director | 65 | $79 |
| John Neis | Director | 10 | $12 |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CLRB quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.